1224373-47-0

Basic information

• Product Name: C₁₁H₁₅BrFN₃O₂
• Synonyms: C₁₁H₁₅BrFN₃O₂
• CAS NO: 1224373-47-0
• Molecular Weight: 320.161
• Mol File: 1224373-47-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₁₁H₁₅BrFN₃O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₁H₁₅BrFN₃O₂(1224373-47-0)
• EPA Substance Registry System: C₁₁H₁₅BrFN₃O₂(1224373-47-0)

Safety Data

• Hazardous Substances Data: 1224373-47-0(Hazardous Substances Data)

Upstream product

• 142-25-6 N,N',N'-trimethylenediamine 
• 147808-42-2 5-bromo-1,3-difluoro-2-nitro-benzene 

Downstream Products

• 1227361-47-8 C₁₂H₁₅BrN₄O₂ 

Relevant articles and documents

QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS

The invention is directed to quinazoline compounds that can inhibit the bioactivity of one or more kinase enzymes, including a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Fit kinase, an Aurora kinase, or a Src kinase, or any combination thereof; to methods of use of those compounds; and to methods of preparation of those compounds. The inventive compounds can be used in the treatment of malconditions including cardiovascular disease, neurogenic pain, hypertension, atherosclerosis, angina, stroke, arterial obstruction, peripheral arterial disease, erectile dysfunction, acute and chronic pain, dementia, Alzheimer's disease, Parkinson's disease, neuronal degeneration, asthma, amyotrophic lateral sclerosis, spinal cord injury, rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, cerebral vasospasm, open angle glaucoma, multiple sclerosis, pulmonary hypertension, acute respiratory distress syndrome, inflammation, diabetes, urinary organ diseases and benign prostatic hypertrophy (BPH), metastasis, cancer, glaucoma, ocular hypertension, retinopathy, autoimmune disease, viral infection, or myocardial pathology.